Therapy of hepatitis C virus-associated glomerulonephritis: current approaches.

Abstract

The most frequent kidney disease associated with chronic hepatitis C virus (HCV) infection is type I membranoproliferative glomerulonephritis (MPGN) in patients with type II mixed cryoglobulinemia. The principal clinical manifestations of glomerular disease in HCV-infected patients are the presence of proteinuria and microscopic hematuria with or without impaired kidney function. Various approaches have been tried for the treatment of HCV-associated glomerulonephritis, including immunosuppressive therapy (corticosteroids and cytotoxic agents), plasma exchange and antiviral agents. Limited data exist regarding antiviral treatment of HCV-associated glomerulonephritis, whereas immunosuppressive agents have been suggested for cryoglobulinemic kidney disease. A recent meta-analysis of controlled clinical trials (CCTs) suggested that standard interferon (IFN) doses were more effective than immunosuppressive agents in lowering proteinuria of patients with HCV-related cryoglobulinemic glomerulonephritis (odds ratio 3.86; 95% confidence interval, 1.44-10.33; p=0.007). However, data for follow-up were not given. Two distinct approaches should be considered for the treatment of HCV-associated cryoglobulinemic glomerulonephritis according to the level of proteinuria and kidney failure. Preliminary studies with rituximab therapy of HCV-related cryoglobulinemic glomerulonephritis have given encouraging results, even if a point of caution is important, because rituximab use may be associated with activation of various infections, including HCV.

• Authors: Fabrizio Fabrizi, Giovanna Lunghi, Piergiorgio Messa, Paul Martin
• Journal: Journal of nephrology (J Nephrol) 2008 Nov-Dec Vol. 21 Issue 6 Pg. 813-25 ISSN: 1121-8428 [Print] Italy
• PMID: 19034865 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20
• Antiviral Agents
• Immunologic Factors
• Ribavirin
• Rituximab
• Interferons

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20
• Antiviral Agents (therapeutic use)
• Clinical Trials as Topic (methods)
• Drug Therapy, Combination
• Glomerulonephritis (drug therapy, etiology)
• Hepacivirus (isolation & purification)
• Hepatitis C, Chronic (complications, drug therapy, virology)
• Humans
• Immunologic Factors (therapeutic use)
• Immunosuppression Therapy (methods)
• Interferons (therapeutic use)
• Ribavirin (therapeutic use)
• Rituximab